Trial Profile
Phase I Study of Vorinostat in Combination With 13-Cis-Retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Isotretinoin (Primary) ; Vorinostat (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- Acronyms NANT
- 23 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2013 Planned end date changed from 1 Dec 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 09 Nov 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.